Naquotinib (ASP8273) is primarily investigated for its application in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer cells exhibit specific mutations in the epidermal growth factor receptor (EGFR). This compound functions as an EGFR tyrosine kinase inhibitor, targeting and blocking the activity of mutated EGFR proteins that drive cancer cell growth. Its use is especially relevant for patients with EGFR T790M mutations, which are often associated with resistance to first-generation EGFR inhibitors. Clinical studies have explored its efficacy in shrinking tumors and improving progression-free survival in affected individuals. Additionally, research has focused on its potential to be administered orally, offering a convenient treatment option for patients. Ongoing trials aim to further evaluate its safety profile and effectiveness in broader NSCLC populations.